Item 7.01 Regulation FD Disclosure.

bluebird bio, Inc. intends to provide investors with an update of its anticipated 2022 regulatory and commercialization milestones across its beta-thalassemia, cerebral adrenoleukodystrophy, and sickle cell disease programs. A copy of the slide that will be used in presentations with investors is being furnished as Exhibit 99.1, which is incorporated herein by reference.

The information in this Current Report on Form 8-K pursuant to Item 7.01 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this Current Report.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits

  Exhibit
    No.                                       Description
   99.1          Presentation slide by bluebird bio. Inc.
    104        Cover Page Interactive Data File (embedded within the Inline XBRL
               document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses